These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 37682390)
1. A review of immune modulators and immunotherapy in infectious diseases. Sangeetha Vijayan P; Xavier J; Valappil MP Mol Cell Biochem; 2024 Aug; 479(8):1937-1955. PubMed ID: 37682390 [TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory approaches for prevention and treatment of infectious diseases. Nijnik A Curr Opin Microbiol; 2013 Oct; 16(5):590-5. PubMed ID: 23870826 [TBL] [Abstract][Full Text] [Related]
3. Small molecule innate immune modulators in cancer therapy. Goswami A; Goyal S; Khurana P; Singh K; Deb B; Kulkarni A Front Immunol; 2024; 15():1395655. PubMed ID: 39318624 [TBL] [Abstract][Full Text] [Related]
4. Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy. Rehman M; Qaiser A; Khan HS; Manzoor S; Ashraf J Clin Exp Med; 2024 Aug; 24(1):180. PubMed ID: 39105978 [TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory metal-based biomaterials for cancer immunotherapy. Yuan K; Zhang C; Pan X; Hu B; Zhang J; Yang G J Control Release; 2024 Nov; 375():249-268. PubMed ID: 39260573 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Interventions to Immunologic and Immune-Mediated Conditions in Horses. Hart KA; Kimura S Vet Clin North Am Equine Pract; 2024 Aug; 40(2):307-339. PubMed ID: 38852015 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulators as an antimicrobial tool. Pirofski LA; Casadevall A Curr Opin Microbiol; 2006 Oct; 9(5):489-95. PubMed ID: 16931122 [TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy for infectious diseases: challenges and prospects]. Karaulov AV; Kaliuzhin OV Ter Arkh; 2013; 85(11):100-8. PubMed ID: 24432609 [TBL] [Abstract][Full Text] [Related]
9. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Buchwald UK; Pirofski L Curr Pharm Des; 2003; 9(12):945-68. PubMed ID: 12678861 [TBL] [Abstract][Full Text] [Related]
10. The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens. Garai P; Gogoi M; Gopal G; Radhakrishnan Y; Nandakumar KS; Chakravortty D Expert Opin Biol Ther; 2014 Oct; 14(10):1383-97. PubMed ID: 24897303 [TBL] [Abstract][Full Text] [Related]
11. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics. Kotraiah V; Phares TW; Browne CD; Pannucci J; Mansour M; Noe AR; Tucker KD; Christen JM; Reed C; MacKay A; Weir GM; Rajagopalan R; Stanford MM; Chung CS; Ayala A; Huang J; Tsuji M; Gutierrez GM Front Immunol; 2020; 11():264. PubMed ID: 32210956 [TBL] [Abstract][Full Text] [Related]
13. The use of antibodies in the treatment of infectious diseases. Chan CE; Chan AH; Hanson BJ; Ooi EE Singapore Med J; 2009 Jul; 50(7):663-72; quiz 673. PubMed ID: 19644620 [TBL] [Abstract][Full Text] [Related]
14. Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders. Hussein NI; Molina AH; Sunga GM; Amit M; Lei YL; Zhao X; Hartgerink JD; Sikora AG; Young S Oral Oncol; 2024 Nov; 158():106986. PubMed ID: 39137489 [TBL] [Abstract][Full Text] [Related]
15. Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity. Lavelle EC; McLachlan JB Curr Opin Pharmacol; 2018 Aug; 41():vii-ix. PubMed ID: 30139514 [No Abstract] [Full Text] [Related]
17. [Indications for passive immunotherapy in infectious diseases]. Baumgartner JD Schweiz Med Wochenschr; 1987 Jan; 117(3):84-90. PubMed ID: 3823822 [TBL] [Abstract][Full Text] [Related]
18. Overview of biologic response modifiers in infectious disease. Masihi KN; Schäfer H Infect Dis Clin North Am; 2011 Dec; 25(4):723-31. PubMed ID: 22054752 [TBL] [Abstract][Full Text] [Related]
19. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Nicholls EF; Madera L; Hancock RE Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578 [TBL] [Abstract][Full Text] [Related]
20. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]